相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations
Hsuan-Ping Chang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody-Drug Conjugate in Sprague Dawley Rats
Victor Yip et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
Hsuan Ping Chang et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs
Brittney J. Mills et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
Chunze Li et al.
MABS (2020)
An in Vitro Assay Using Cultured Kupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo Antibody Pharmacokinetics
David W. Meyer et al.
MOLECULAR PHARMACEUTICS (2020)
Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates
Peiying Zuo
AAPS JOURNAL (2020)
Characterization of T-DM1-resistant breast cancer cells
Juliette Sauveur et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Antibody Conjugates-Recent Advances and Future Innovations
Donmienne Leung et al.
ANTIBODIES (2020)
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Renata Zajaczkowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Antibody-drug conjugates for cancer
Cindy H. Chau et al.
LANCET (2019)
Cleavable linkers in antibody-drug conjugates
Jonathan D. Bargh et al.
CHEMICAL SOCIETY REVIEWS (2019)
Responsive Antibody Conjugates Enable Quantitative Determination of Intracellular Bond Degradation Rate
Michelle R. Sorkin et al.
CELL CHEMICAL BIOLOGY (2019)
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
Joanna C. Masters et al.
INVESTIGATIONAL NEW DRUGS (2018)
The neutrophil: one cell on many missions or many cells with different agendas?
Gustaf Christoffersson et al.
CELL AND TISSUE RESEARCH (2018)
Challenges and new frontiers in analytical characterization of antibody-drug conjugates
Anil Wagh et al.
MABS (2018)
Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice
Yasuaki Anami et al.
NATURE COMMUNICATIONS (2018)
Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology
Danielle Mandikian et al.
AAPS JOURNAL (2018)
Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future
Heather E. Vezina et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches
Miro J. Eigenmann et al.
JOURNAL OF PHYSIOLOGY-LONDON (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1
Antari Khot et al.
AAPS JOURNAL (2017)
Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE
Aman P. Singh et al.
DRUG METABOLISM AND DISPOSITION (2017)
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)
Aman P. Singh et al.
AAPS JOURNAL (2016)
Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma
Cong Wei et al.
ANALYTICAL CHEMISTRY (2016)
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates
Jose F. Ponte et al.
BIOCONJUGATE CHEMISTRY (2016)
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Aman P. Singh et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Magdalena Dorywalska et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic
Nicola J. Stagg et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2016)
Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
Andrew B. Waight et al.
PLOS ONE (2016)
Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper
Eugenia Kraynov et al.
DRUG METABOLISM AND DISPOSITION (2016)
Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers
Kedan Lin et al.
CLINICAL CANCER RESEARCH (2015)
A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development
Shingo Oda et al.
DRUG METABOLISM AND PHARMACOKINETICS (2015)
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
Robert P. Lyon et al.
NATURE BIOTECHNOLOGY (2015)
Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development
Aman P. Singh et al.
PHARMACEUTICAL RESEARCH (2015)
Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates
Yuan Chen et al.
CLINICAL PHARMACOKINETICS (2015)
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Amrita V. Kamath et al.
PHARMACEUTICAL RESEARCH (2015)
Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
Siddharth Sukumaran et al.
PHARMACEUTICAL RESEARCH (2015)
A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate
Dhaval K. Shah et al.
AAPS JOURNAL (2014)
A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
Brendan Bender et al.
AAPS JOURNAL (2014)
Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy
Aparna Areti et al.
REDOX BIOLOGY (2014)
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2
C. Andrew Boswell et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Antibody biodistribution coefficients Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human
Dhaval K. Shah et al.
MABS (2013)
Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective
Dhaval K. Shah et al.
BIOANALYSIS (2013)
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper
Boris Gorovits et al.
BIOANALYSIS (2013)
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
Surinder Kaur et al.
BIOANALYSIS (2013)
Carboxylesterases Are Uniquely Expressed among Tissues and Regulated by Nuclear Hormone Receptors in the Mouse
Ryan D. Jones et al.
DRUG METABOLISM AND DISPOSITION (2013)
ADME of Antibody-Maytansinoid Conjugates
Hans K. Erickson et al.
AAPS JOURNAL (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
Dhaval K. Shah et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
Dhaval K. Shah et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen et al.
NATURE BIOTECHNOLOGY (2012)
Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats
C. Andrew Boswell et al.
BIOCONJUGATE CHEMISTRY (2011)
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Rebecca A. Herbertson et al.
CLINICAL CANCER RESEARCH (2009)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
